GLP-1 Supply Crunch Set to Extend Through 2025 as Demand Outpaces Production
Widespread supply shortages for popular GLP-1 weight loss medications are projected to continue deep into 2025 due to manufacturing limits and overwhelming cons
By Foodie Pundit Newsroom - Published - Updated - Section: Glp1 Weight Loss
Key points
- Manufacturing bottlenecks and high demand will keep Ozempic and Wegovy hard to find throughout 2025.
- Pharmacies continue to face rolling stockouts, driving interest in compounded alternatives despite regulatory cautions.
- Unpredictable medication access is creating volatile, short-term shifts in consumer food spending and dining habits.
- Relief depends on long-term facility expansions and the future arrival of easier-to-produce oral tablet options.
This report is part of Foodie Pundit premium coverage. Foodie Pundit members read the full story. See membership.
Sources and methodology
Reported from the public datasets below.
More from the Foodie Pundit Newsroom
- FDA Warns Against Dangerous Sleepy Chicken TikTok Cooking Trend
- Burger King Revives Whopper Wednesday Deal As Quick Service Value Wars Intensify
- Indianapolis Restaurant Sector Expands with Diverse New Culinary Concepts
- How the Viral Cottage Cheese Wrap Is Redefining Retail Protein Trends
- Alternative Seafood Gains Traction as Food Science Transforms Menu Options